Compare ING Groep NV (ING) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Nuwellis Inc — how do they compare? ING Groep NV trades at $33.26 (market cap $93.76B), while Nuwellis Inc trades at $0.7 (market cap $2.20M). The key difference: ING Groep NV is far larger — about 42618.2× Nuwellis Inc's market cap, and ING Groep NV pays a 3.95% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 93 Days and Nuwellis Inc for 26 Days on average.
| ING | NUWE | |
|---|---|---|
Market Cap | $93.76B | $2.20M |
Volume | 4,620,220 | 121,544 |
Sector | Financials | Health |
52-Week High | $37.27 | $146.65 |
52-Week Low | $23.66 | $0.68 |
Typical Hold Time | 93 Days | 26 Days |
Enterprise Value | $236.48B | -$1.52M |
Dividend Yield | 3.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING stock trades at $33.92, down 2.81% today, with a bearish technical outlook despite recent earnings beats. The company shows strong profitability with 28.34% net income margin and 13.49% ROE, supported by management's raised ROE target above 16% for 2027. Recent news highlights strategic focus on organic growth and bolt-on acquisitions while maintaining capital discipline.
While analyst consensus remains strongly bullish with 65% buy ratings, negative cash flow trends and regulatory scrutiny in Australia present near-term risks. The stock's attractive valuation at 12.86 P/E offers potential upside if the company can execute on its growth strategy and improve cash generation.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
